Cargando…

Elevated hepatocyte growth factor expression as an autocrine c‐Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and the third leading cause of cancer‐related deaths worldwide. Limitations in HCC treatment result due to poor prognosis and resistance against traditional radiotherapy and chemotherapies. The multikinase inhibitor soraf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Firtina Karagonlar, Zeynep, Koc, Dogukan, Iscan, Evin, Erdal, Esra, Atabey, Neşe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832867/ https://www.ncbi.nlm.nih.gov/pubmed/26790028 http://dx.doi.org/10.1111/cas.12891

Ejemplares similares

Doxorubicin‐induced senescence promotes stemness and tumorigenicity in EpCAM−/CD133− nonstem cell population in hepatocellular carcinoma cell line, HuH‐7
por: Karabicici, Mustafa, et al.
Publicado: (2021)

Heparin Inhibits Hepatocyte Growth Factor Induced Motility and Invasion of Hepatocellular Carcinoma Cells through Early Growth Response Protein 1
por: Ozen, Evin, et al.
Publicado: (2012)

Changes in Wnt and TGF-β Signaling Mediate the Development of Regorafenib Resistance in Hepatocellular Carcinoma Cell Line HuH7
por: Karabicici, Mustafa, et al.
Publicado: (2021)

Thioredoxin interacting protein promotes invasion in hepatocellular carcinoma
por: Gunes, Aysim, et al.
Publicado: (2018)

A Novel Function for KLF4 in Modulating the De-Differentiation of EpCAM(−)/CD133(−) nonStem Cells into EpCAM(+)/CD133(+) Liver Cancer Stem Cells in HCC Cell Line HuH7
por: Firtina Karagonlar, Zeynep, et al.
Publicado: (2020)

Reciprocal Activating Crosstalk between c-Met and Caveolin 1 Promotes Invasive Phenotype in Hepatocellular Carcinoma
por: Korhan, Peyda, et al.
Publicado: (2014)

Increased telomerase activity in major depressive disorder with melancholic features: Possible role of pro-inflammatory cytokines and the brain-derived neurotrophic factor
por: Bürhan-Çavuşoğlu, Pınar, et al.
Publicado: (2021)

Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis
por: Bozkaya, Giray, et al.
Publicado: (2012)

Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma
por: KUNTER, IMGE, et al.
Publicado: (2014)

Differential expression of Caveolin-1 in hepatocellular carcinoma: correlation with differentiation state, motility and invasion
por: Cokakli, Murat, et al.
Publicado: (2009)

lncRNA HOTAIR overexpression induced downregulation of c-Met signaling promotes hybrid epithelial/mesenchymal phenotype in hepatocellular carcinoma cells
por: Topel, Hande, et al.
Publicado: (2020)

Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells
por: Han, Peng, et al.
Publicado: (2017)

Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells
por: Yuzugullu, Haluk, et al.
Publicado: (2009)

Hepatocyte Growth Factor Receptor c-Met Instructs T Cell Cardiotropism and Promotes T Cell Migration to the Heart via Autocrine Chemokine Release
por: Komarowska, Izabela, et al.
Publicado: (2015)

A Natural Hepatocyte Growth Factor/Scatter Factor Autocrine Loop in Myoblast Cells and the Effect of the Constitutive Met Kinase Activation on Myogenic Differentiation
por: Anastasi, Sergio, et al.
Publicado: (1997)

An autophagy-inducing stapled peptide promotes c-MET degradation and overrides adaptive resistance to sorafenib in c-MET(+) hepatocellular carcinoma
por: Gao, Shan, et al.
Publicado: (2022)

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
por: Kentsis, Alex, et al.
Publicado: (2012)

LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells
por: Ma, Yongfang, et al.
Publicado: (2021)

Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma
por: Zhu, Qiankun, et al.
Publicado: (2020)

Activin A is a prominent autocrine regulator of hepatocyte growth arrest
por: Haridoss, Srividyameena, et al.
Publicado: (2017)

Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma
por: Jiang, Xiufeng, et al.
Publicado: (2015)

Autocrine EGF and TGF‐α promote primary and acquired resistance to ALK/c‐Met kinase inhibitors in non‐small‐cell lung cancer
por: Wang, Yueqin, et al.
Publicado: (2022)

High glucose induced c-Met activation promotes aggressive phenotype and regulates expression of glucose metabolism genes in HCC cells
por: Topel, Hande, et al.
Publicado: (2021)

Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
por: Decaens, Thomas, et al.
Publicado: (2021)

Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis
por: Hsu, Tung-Wei, et al.
Publicado: (2023)

Non-autocrine, constitutive activation of Met in human anaplastic thyroid carcinoma cells in culture
por: Bergström, J D, et al.
Publicado: (1999)

Liver X Receptor Agonism Sensitizes a Subset of Hepatocellular Carcinoma to Sorafenib by Dual-Inhibiting MET and EGFR
por: Shao, Weiqing, et al.
Publicado: (2019)

Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
por: Decaens, Thomas, et al.
Publicado: (2021)

Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications
por: García-Vilas, Javier A, et al.
Publicado: (2018)

Pleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma
por: Korhan, Peyda, et al.
Publicado: (2018)

Elevated autocrine EDIL3 protects hepatocellular carcinoma from anoikis through RGD-mediated integrin activation
por: Feng, Ming-Xuan, et al.
Publicado: (2014)

Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607
por: Dai, Yao, et al.
Publicado: (2012)

Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma
por: Kuczynski, Elizabeth A., et al.
Publicado: (2016)

Paracrine and autocrine regulation of gene expression by Wnt-inhibitor Dickkopf in wild-type and mutant hepatocytes
por: Hartung, Niklas, et al.
Publicado: (2017)

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
por: Ryoo, Baek-Yeol, et al.
Publicado: (2021)

Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma
por: Liu, Jianhua, et al.
Publicado: (2017)

Molecular mechanisms controlling the phenotype and the EMT/MET dynamics of hepatocyte
por: Cicchini, Carla, et al.
Publicado: (2015)

Hepatocyte growth factor/MET in cancer progression and biomarker discovery
por: Matsumoto, Kunio, et al.
Publicado: (2017)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_0d6bm1dh0hpn38kpgqbkmo32dm